Appointments at the Communications Department of the sanofi-aventis Group

Sep 22, 2004, 01:00 ET from The sanofi-aventis Group

    PARIS, Sept. 22 /PRNewswire-FirstCall/ --  The sanofi-aventis Group
 announced today the appointments within the Communications department of the
 Group, which is headed by Nicole CRANOIS, Senior Vice President,
      - Jocelyne COUPAT,      Vice President, International Relations
      - Agnes GARCIA-GIBOT,   Vice President, Internal Communications
                              and Corporate Image
      - Michel JOLY,          Vice President, Product PR
      - William BRATTON,      Deputy Vice President, Product PR
      - Jean-Marc PODVIN,     Vice President, Media Relations
      - Robert SEBBAG,        Vice President, Solidarity mission on access to
      Are also members of the Communications Management Committee:
      - Xavier LEGRAND DU LAURENS,   Vice President, Communications France
      - Miriam HENN,                 Vice President, Communications Germany
      - Charles F. ROUSE,            Vice President, Communications USA.
     The sanofi-aventis Group is the world's 3rd largest pharmaceutical
 company, ranking number 1 in Europe.   Backed by a world-class R&D
 organization, sanofi-aventis is developing leading positions in seven major
 therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes,
 central nervous system, internal medicine, vaccines. The sanofi-aventis Group
 is listed in Paris (EURONEXT: SAN) and in New York (NYSE:   SNY).
     Important Information
     In connection with its acquisition of Aventis, Sanofi-Aventis has
 announced that it is studying the feasibility of merging Aventis with and into
 Sanofi-Aventis, with Sanofi-Aventis continuing as the surviving corporation.
 In connection with any merger of Aventis into Sanofi-Aventis, Sanofi-Aventis
 will file a post-effective amendment to its registration statement on Form F-4
 (File no. 333-112314), which will include a prospectus relating to the merger,
 and will file additional documents with the SEC.  Investors are urged to read
 the registration statement, including any preliminary prospectus or definitive
 prospectus (when available) relating to the merger, and any other relevant
 documents filed with the SEC, including all amendments and supplements,
 because they will contain important information.  Free copies of the
 registration statement, as well as other relevant documents filed with the
 SEC, may be obtained at the SEC's web site at  At the appropriate
 time, Sanofi-Aventis will provide investors with information on how to obtain
 any merger-related documents for free from Sanofi-Aventis or from its duly
 appointed agents.
      CONTACT:  Jean-Marc Podvin
                Vice President, Media Relations

SOURCE The sanofi-aventis Group